{
    "clinical_study": {
        "@rank": "100882", 
        "brief_summary": {
            "textblock": "To assess in an exploratory manner, the pronostic utility for locoregional control,\n      progression-free and distant metastasis-free survival  of a pre-therapy and post-therapy\n      blood DNA test of HPV E6 and E7 DNA for subtypes 16 and 18 in p16+ and/or HPV+ oropharyngeal\n      cancer patients.  This will entail analysis of both initial pre-therapy HPV level as a\n      continuous variable and initial post-therapy HPV level as a dichotomous variable."
        }, 
        "brief_title": "HPV Serum DNA Levels Predicting Outcome in p16+ Squamous Cell Head and Neck Cancer", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Subjects With p16+/HPV+ Squamous Cell Carcinomas of the Oropharynx.", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Head and Neck Neoplasms", 
                "Oropharyngeal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histoloically proven primary cancer of the oropharynx, p16(+) and/or HPV (+), who are\n             planned for treatment with resection, radiation and/or chemotherapy.\n\n          -  Subsites of oropharynx:include tonsil, base of tongue, vallecula, oropharyngeal wall,\n             soft palate, glossotonsillar sulcus.\n\n          -  No or minimal smaoking history (=10 pack-year, no smoking in the last 10 years based\n             on documented history and/or subject report)\n\n          -  Age 18 years or older\n\n          -  Subjects are capable of giving informed consent or have an acceptabl;e surrogate\n             capable of giving consent on the subjects behalf.\n\n          -  Enrollment on any other study, regardless of therapy is allowed.\n\n          -  Enrollment on any other tumor or tissue banking study is allowed.\n\n          -  Patients who have had blood drawn as part of another study, including the\n             IRB-approved ENT Tumor Bank Study, may be included in this study even if the patient\n             has already had surgery.\n\n        Exclusion Criteria:\n\n          -  Previous chemotherapy or radiation therapy to the head and neck unrelated to current\n             disease.\n\n          -  Previous surgery for head and neck cancer unrelated to current disease.\n\n          -  Widespread , biopsy-proven metastatic disease (stage IVC disease) at time of\n             presentation (small indeterminate lung or mediastinal nodules are allowed)\n\n          -  Patients who have started induction chemotherapy prior to consideration for study\n             eligibility.\n\n          -  Another active cancer except nonmelanomatous skin cancer.\n\n          -  History of cervical penile or anal cancer.\n\n          -  Patient treated with surgery, adjuvant radiation therapy or chemotherapy outside of\n             the University of Pennsylvania.\n\n          -  History of smoking in the last 10 years.\n\n          -  History of 10 pack-years of cigarette smoking based on documented history and/or\n             subject report\n\n          -  Presence of sidespread leukoplakia or erythroplakia."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01984359", 
            "org_study_id": "UPCC 22313"
        }, 
        "intervention": {
            "intervention_name": "Obtaining Human tissue", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 8, 2013", 
        "location": {
            "contact": {
                "email": "PennCancerTrials@emergingmed.com", 
                "last_name": "Peter Ahn, MD", 
                "phone": "855-216-0098"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Abramson Cancer Center of the University of Pennsylvania"
            }, 
            "investigator": {
                "last_name": "Peter Ahn, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Pilot, Single-Center Study Of Quantitative HPV Serum Or Plasma DNA As A Prognostic Marker In P16+/HPV+ Squamous Carcinomas Of The Oropharynx And Unknown Primary Head And Neck Cancers", 
        "overall_contact": {
            "email": "PennCancerTrials@emergingmed.com", 
            "last_name": "Peter Ahn, MD", 
            "phone": "855-216-0098"
        }, 
        "overall_official": {
            "affiliation": "Abramson Cancer Center of the University of Pennsylvania", 
            "last_name": "Peter Ahn, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of subjects with Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01984359"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Abramson Cancer Center of the University of Pennsylvania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abramson Cancer Center of the University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}